Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Innovus Pharmaceuticals, Inc. (OTC: INNV).

Full DD Report for INNV

You must become a subscriber to view this report.


Recent News from (OTC: INNV)

Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men...
Source: Business Wire
Date: August, 29 2018 06:05
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and Raises Target Price to $0.75
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) and has raised its target pri...
Source: ACCESSWIRE IA
Date: August, 21 2018 09:00
Innovus Pharmaceuticals, Inc. (INNV) CEO Bassam Damaj on Q2 2018 Results - Earnings Call Transcript
Innovus Pharmaceuticals, Inc. (INNV) Q2 2018 Earnings Conference Call August 14, 2018 04:15 PM ET Executives Bassam Damaj - President and CEO Randy Berholtz - EVP, Corporate Development and General Counsel Ryan Selhorn - VP and CFO Presentation Operator Good day and wel...
Source: SeekingAlpha
Date: August, 14 2018 22:56
Innovus Pharma Reports New Quarterly Revenue Record of $7.3 million for the Second Quarter 2018 and Expands to Canadian Market
Beyond Human™ Sales & Marketing Strategy Results in 258.7% Net Revenue Growth Compared to Same Period in 2017 Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), today reported results for the second quarter 2018. ...
Source: Business Wire
Date: August, 14 2018 16:10
Innovus Pharma Signs Purchase Agreement with "Showcase - The Home of the Hottest Trends" to Sell the Company's Apeaz® Cream for the Relief of Arthritis Pain in Its 110 "Showcase" Retail Stores in the United States and Canada
Apeaz® is the Fifth Company Product to Be Sold in Retails Stores in the U.S. and Canada Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovati...
Source: Business Wire
Date: August, 10 2018 06:10
Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax(TM)
The Three Potential Products, If Approved, Will Supplement the Company’s Eight Products Launched in Canada to Date Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceut...
Source: Business Wire
Date: August, 07 2018 06:05
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at...
Source: Business Wire
Date: August, 03 2018 06:00
Innovus Pharma inks deal with CVS Pharmacy to sell Androferti to increase sperm quality
Innovus Pharmaceuticals ( OTCQB:INNV ) has entered into a pilot program with CVS Pharmacy, a subsidiary of CVS Health Corp. (NYSE: CVS ), to sell Androferti, to increase sperm quality. More news on: Innovus Pharmaceuticals, Inc., CVS Health Corporation, Healthcare stocks news, Read m...
Source: SeekingAlpha
Date: July, 19 2018 07:51
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men's Clinic
CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture ...
Source: Business Wire
Date: July, 19 2018 06:05
Innovus Pharmaceuticals reports preliminary Q2 results
Innovus Pharmaceuticals ( OTCQB:INNV ) announces preliminary Q2 net revenue between $6.6M to $6.8M, ~47-51% increase from Q1 and ~330-340% increase from Q2 2017. More news on: Innovus Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 17 2018 08:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.1010.100.1040.0981295,500
2018-12-070.1050.10110.1050.101225,798
2018-12-060.1030.103920.110.101300,865
2018-12-050.10630.1080.110.106335,600
2018-12-040.10630.1080.110.106335,600

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10138,200295,50046.7682Short
2018-12-07119,666225,79852.9969Short
2018-12-06156,062300,86551.8711Short
2018-12-0411,60035,60032.5843Cover
2018-12-0333,030115,03028.7142Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INNV.


About Innovus Pharmaceuticals, Inc. (OTC: INNV)

Logo for Innovus Pharmaceuticals, Inc. (OTC: INNV)

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men s and women s health and vitality. The Company generates revenues from its lead products Zestra for female arousal and EjectDelay for premature ejaculation and has a total of five marketed products in this space, including Sensum for the indication of reduced penile sensitivity, for sales outside the U.S. only , Zestra Glide, Vesele for promoting sexual and cognitive health, Androferti in the US and Canada to support overall male reproductive health and sperm quality and FlutiCare OTC for Allergic Rhinitis. Innovus Pharma s mission is to in license, acquire or develop over the counter and consumer healthcare products designed for in home treatment of medical conditions and ailments to help people take care of themselves and their families in order to live healthy lives.

 

 

 

Current Management

  • Bassam Damaj, Ph D / President, CEO, IR
    • Dr. Bassam Damaj was appointed to serve as our President amp CEO on January , . Prior to joining Innovus Pharma, Dr. Damaj served as President amp Chief Executive Officer of Apricus Biosciences, Inc., NASDAQ: APRI from December until November . At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug, Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, NovartisSandoz and Takeda. Before Apricus Bio, Dr. Damaj was a cofounder of BioQuant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of BioQuant s Board of Directors from its inception in June until its acquisition by Apricus Biosciences in December . In addition, Dr. Damaj was the founder, Chairman, President amp Chief Executive Officer of R amp D Healthcare, and the cofounder of Celltek Biotechnologies. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in . Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
  • Rauly Gutierrez / VP, Fin.
    • Mr. Gutierrez was appointed as our Vice President of Finance on September , , and was appointed our Principal Financial and Accounting Officer effective April , . He was recently an Audit Senior Manager at KMJ Corbin amp Company LLP, a regional public accounting firm. Mr. Gutierrez began his career at KMJ Corbin amp Company in and mainly serviced clients in the pharmaceutical and life science industries which included multiple publiclytraded companies with market caps ranging from million to billion and revenues ranging from prerevenue to million. He has a wide range of experience dealing with SEC and Act filings, including IPOs, reverse mergers, SEC comment letters, SarbanesOxley Act attestation services and periodic SEC reporting requirements. His areas of expertise include complex debt and equity transactions, such as derivatives, convertible instruments, and stockbased compensation. He also has expertise in accounting for grosstonet revenue recognition for pharmaceutical product sales, pharmacy drug billings and in business combination transactions. Mr. Gutierrez received his Bachelor of Science Degree in Accounting from the Leventhal School of Accounting at the University of Southern California, and is licensed as a CPA in the State of California. He is also a member of the AICPA, CalCPA and the Association for Corporate Growth.
  • Randy Berholtz / General Counsel
    • Mr. Randy Berholtz is our Executive Vice President, General Counsel and Secretary. He is the former Executive Vice President, General Counsel and Secretary of Apricus Biosciences, Inc. NASDAQ: APRI , a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and US life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company and the Interim General Counsel and Secretary of Nanogen, Inc. NASDAQ: NGEN , a genomics tools company. He has also been an attorney with the law firms of Heller Ehrman, LLP, Cooley Godward, LLP, Kirkpatrick amp Lockhart, LLP now K amp L Gates and Cravath, Swaine amp Moore. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University, where he was a Rhodes Scholar, and a Juris Doctor degree from Yale Law School where he was a Senior Editor of The Yale Law Journal.
  • Henry Esber / Chairman
    • Henry Esber, Ph.D. is the Chairman of the Board since and has served as a Director since January . In , Dr. Esber cofounded BioQuant, Inc. and served as its Senior Vice President and Chief Business Development Officer from . Dr. Esber has over years of experience in the pharmaceutical service industry, including tenures as Executive Director of Business Development at Charles River Laboratories and Director of the Department of Immunology and Clinical Services at TSI Mason. Dr. Esber also served on the Board of Directors of Apricus Biosciences, Inc. NASDAQ: APRI and currently serves on the Board of Directors at several privately held pharmaceutical companies.
  • Bassam Damaj, Ph D / Director
    • Dr. Bassam Damaj was appointed to serve as our President amp CEO on January , . Prior to joining Innovus Pharma, Dr. Damaj served as President amp Chief Executive Officer of Apricus Biosciences, Inc., NASDAQ: APRI from December until November . At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug, Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, NovartisSandoz and Takeda. Before Apricus Bio, Dr. Damaj was a cofounder of BioQuant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of BioQuant s Board of Directors from its inception in June until its acquisition by Apricus Biosciences in December . In addition, Dr. Damaj was the founder, Chairman, President amp Chief Executive Officer of R amp D Healthcare, and the cofounder of Celltek Biotechnologies. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in . Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
  • Vivian Liu / Director
    • Vivian Liu has served as a Director since January . Additionally, Ms. Liu served as our President amp CEO from January to January . In , Ms. Liu cofounded NexMed, Inc., which was renamed Apricus Biosciences, Inc. NASDAQ: APRI in . Ms. Liu served as NexMed s President and Chief Executive Officer from , after having served in various executive capacities. Ms. Liu was appointed to the NexMed Board of Directors in and served as its Chairman of the Board from . Prior to cofounding NexMed, Ms. Liu was the Commercial Attach with the Delegation of Quebec in Los Angeles, responsible for business development projects for the medical, pharmaceutical and biotechnology industries. Ms. Lui is currently the Managing Director of OxOnc Services Company, a partner in OxOnc Development LP, a privately held oncology development company funded by Orbimed Advisors.
  • Ziad Mirza / Director
    • Ziad Mirza, M.D. has served as a Director since March and was previously Chairman of the Board from March to . Dr. Mirza is President and cofounder of Baltimore Medical and Surgical Associates and currently serves as the Medical Director of six nursing homes in the Baltimore area and as the Medical Director of The Greater Baltimore Medical Center Wound Care and Hyperbaric Unit. Additionally, Dr. Mirza is currently enrolled as an investigator in Stem Cell Research in Diabetic Foot Ulcers. Dr. Mirza is double boarded in Internal Medicine, Dive and Hyperbaric Medicine and in Dr. Mirza became a Certified Medical Director of longterm care through the American Medical Directors Association. In October Dr. Mirza received accreditation as a Certified Physician Executive from the American College of Physician Executives ACPE and in he obtained his MBA in Health Care from the University of Massachusetts.

Current Share Structure

  • Market Cap: $24,500,679 - 03/15/2018
  • Authorized: 300,000,000 - 09/25/2017
  • Issue and Outstanding: 164,434,088 - 11/10/2017
  • Float: 108,530,426 - 09/25/2017

 


Recent Filings from (OTC: INNV)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: INNV)

Daily Technical Chart for (OTC: INNV)


Stay tuned for daily updates and more on (OTC: INNV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: INNV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INNV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INNV and does not buy, sell, or trade any shares of INNV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/